TRIAL DETAIL
CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor |
|||
NCT#: |
||||
Conditions: |
Gastrointestinal Stromal Tumor; Sarcoma |
|||
Status: |
Completed |
|||
Phase: |
2 |
Start Date 06/01/2004 |
Age of Trial (yrs) 20.6 |
|
Treatment Phase: |
All |
|||
Drug Category: |
mTOR inhibitor |
|||
Strategy: |
Block KIT Signal Path |
|||
Trial Type: |
Specifically GIST plus other cancers |
|||
Other Protocol IDs: |
CDR0000372912, MAYO-MC027B, NCI-6156 |
|||
Sponsor: |
Mayo Clinic
NCI |
|||
Patient Contact: |
||||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Intravenous |
|||
Trial Notes: |
In this trial, CCI-779 failed to demonstrated promising activity in patients with advanced soft tissue sarcoma. Although imatinib-resistant GIST patients were allowed in the trial, there were no reports of GIST patients actually participating according to the trial results presented at the 2006 ASCO meeting. |
|||
Trial Links |
Trial Results |
Drug Information |
| Torisel prescribing information (PDF) |
| Toricel.com |
| Temsirolimus in Wikipedia |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
Rochester |
MN |
55905 |
USA |